Physician profile
Dean A Le
NPI 1982627089
$23,784.64
in general payments reported to CMS, 2019-2025
75 companies · $7,637 in 2025
The $7,637 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,325 · 2020: $528 · 2021: $1,110 · 2022: $3,133 · 2023: $4,611 · 2024: $4,440 · 2025: $7,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,479.70 |
| Education | $207.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.05 | 2021-2025 | |
| Ucb, INC. | $2,246.21 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,589.37 | 2019-2025 | Ultomiris, Soliris, Koselugo |
| Neurocrine Biosciences, INC. | $1,469.40 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $1,467.17 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,306.92 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Sk Life Science, INC. | $861.97 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $846.29 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $816.60 | 2019-2025 | |
| Lundbeck LLC | $682.02 | 2019-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $559.15 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $501.61 | 2019-2025 | Uplizna, Aimovig |
| Pfizer INC. | $487.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $467.23 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $467.08 | 2019-2025 | Crexont, Rytary |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $421.02 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Janssen Biotech, INC. | $416.52 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.49 | 2021-2025 | Hyqvia, Gammagard |
| Grifols USA, LLC | $350.29 | 2022-2025 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $344.94 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $313.58 | 2023-2025 | Rexulti |
| Celgene Corporation | $311.36 | 2019-2025 | Zeposia |
| Allergan, INC. | $286.49 | 2019-2022 | |
| Abbott Laboratories | $284.94 | 2022-2025 | Infinity, Eterna |
| Ani Pharmaceuticals, INC. | $276.96 | 2023-2024 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $251.74 | 2023-2024 | Wakix |
| Genentech USA, INC. | $230.89 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $220.71 | 2020-2022 | |
| Livanova USA, INC. | $212.87 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Merz Pharmaceuticals, LLC | $184.23 | 2021-2025 | Xeomin, Inbrija |
| Mdd US Operations, LLC | $171.75 | 2023-2025 | Gocovri, Gocovri |
| Medtronic USA, INC. | $170.11 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $165.41 | 2022-2023 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $164.08 | 2021-2025 | Wainua |
| Adamas Pharmaceuticals, INC. | $139.51 | 2019-2020 | |
| Axsome Therapeutics, INC. | $139.50 | 2025 | Symbravo |
| Csl Behring | $137.87 | 2019-2024 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $127.85 | 2022 | |
| Boston Scientific Corporation | $125.77 | 2019-2024 | |
| Horizon Therapeutics Plc | $124.89 | 2022-2023 | Uplizna |
| Tanabe Pharma America, INC. | $124.19 | 2019-2025 | Radicava |
| Avion Pharmaceuticals | $118.03 | 2022-2023 | Dhivy |
| Ge Healthcare | $116.75 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $96.76 | 2019-2023 | Nuplazid |
| Genzyme Corporation | $96.74 | 2019-2023 | |
| Corium, LLC | $86.42 | 2022-2023 | Adlarity |
| Ipsen Biopharmaceuticals, INC | $85.04 | 2024 | Dysport |
| Averitas Pharma INC. | $77.27 | 2023-2024 | Qutenza |
| Upsher-Smith Laboratories LLC | $73.40 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $71.20 | 2023-2024 | Amvuttra |
| Scilex Pharmaceuticals INC. | $68.28 | 2024-2025 | |
| Medtronic, INC. | $52.27 | 2022 | |
| Supernus Pharmaceuticals, INC. | $51.15 | 2019 | |
| Vanda Pharmaceuticals INC. | $49.95 | 2024-2025 | Ponvory |
| Arbor Pharmaceuticals, INC. | $46.55 | 2019-2022 | |
| Strongbridge US INC. | $45.39 | 2019-2020 | |
| Neuropace, INC. | $44.71 | 2022 | |
| Kyowa Kirin, INC. | $42.27 | 2022-2024 | Nourianz |
| Revance Therapeutics, INC. | $41.45 | 2024-2025 | Daxxify |
| Biohaven Pharmaceuticals, INC. | $38.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.75 | 2022-2023 | Keveyis |
| Alfasigma USA, INC. | $32.40 | 2020-2021 | |
| Assertio Therapeutics, INC. | $31.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.37 | 2020 | |
| Mallinckrodt Enterprises LLC | $25.54 | 2019 | |
| Abb Con-Cise Optical Group LLC | $25.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.24 | 2019 | |
| Acorda Therapeutics, INC | $23.49 | 2019 | |
| Vertical Pharmaceuticals, LLC | $23.23 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $22.89 | 2022 | |
| Tonix Medicines, INC. | $21.58 | 2025 | Zembrace Symtouch |
| Biotronik INC. | $17.74 | 2023 | Biomonitor |
| Janssen Pharmaceuticals, INC | $16.51 | 2019 | |
| Cranial Technologies, INC | $14.73 | 2019 | |
| Dynasplint Systems INC. | $5.85 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.